Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

  title={Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia},
  author={Zolt{\'a}n M{\'a}trai and Hajnalka Andrikovics and Anik{\'o} Szilv{\'a}si and Andras Bors and Andr{\'a}s Kozma and Emma {\'A}d{\'a}m and Gabriella Halm and {\'E}va Kar{\'a}szi and Attila Tordai and Tam{\'a}s Masszi},
  journal={Pathology \& Oncology Research},
The marked clinical heterogeneity of CLL makes early prognosis assessment important. Lipoprotein lipase (LPL) has been shown to confer adverse prognosis in CLL, recent data indicating it might also contribute to CLL cell survival and metabolism. We determined LPL mRNA expression in unselected peripheral blood of 84 CLL patients by RT PCR. Results were correlated with other prognostic markers and outcome. 30/84 (40 %) of cases were LPL positive based on the cutoff established by ROC analysis. In… 

Figures and Tables from this paper

Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
LPL expression was found to be closely correlated with IGHV gene mutational status and overall survival, proving LPL as prognostic marker in CLL.
Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia
ApoA is of prognostic value in CLL, and is a potential therapy for CLL patients, and a new risk scoring system named ARAA-score is capable of assessing OS and PFS of CLL Patients.
CYP2B6 polymorphism and lipoprotein lipase expression in chronic lymphocytic leukemia: impact on the outcome of fludarabine–cyclophosphamide regimen
YP2B6FNx016 infers lower CPA efficacy with lower treatment-induced side effects and increased risk of nonresponding to FC chemotherapy in CLL, indicating poor survival.
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression
Despite LPL being found to be a reliable molecular marker for CLL prognosis, its functional role and the molecular mechanisms regulating its expression are still matter of debate and some insights are provided into where currently unexplored questions may lead to.
Signaling lymphocytic activation molecule family-1 (CD150) expression as a prognostic indicator in patients with chronic lymphocytic leukemia
CD150 expression was decreased in CLL patients compared with the control group, with great heterogeneity between CLL Patients, and can be a useful tool in identifying B-CLL patient’s risk.
Endocytosis of very low-density lipoprotein particles: an unexpected mechanism for lipid acquisition by breast cancer cells
The data support a model in which LPL is bound to a heparin-like heparan sulfate proteoglycan motif on the BC cell surface and acts in concert with the VLDL receptor to rapidly internalize intact lipoproteins via receptor-mediated endocytosis.


The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.
It is demonstrated that LPL expression is a predictor for survival in CLL, and for this purpose is as good as IGVH mutational status and more reliable than ZAP70 expression when tested in unpurified CLL samples.
Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia
A role for LPL as a novel prognostic indicator in B-CLL is confirmed after quantifying their expression in peripheral blood mononuclear cells using quantitative reverse transcriptase-polymerase chain reaction (RQ-PCR) in a cohort of 133 patients and correlated the results with clinical outcome, and other known prognostic factors.
Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia.
A quantitative PCR method for determining lipoprotein lipase (LPL) mRNA expression does not require cell purification, and its applicability with archived samples facilitates its use in the clinical routine and other studies.
Expression level of lipoprotein lipase in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors
It was showed that LPL expression correlates with IgVH mutational status and other clinical or laboratory prognostic factors, and might be applied for the assessment of prognosis in patients with CLL.
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia
The data establish LPL as a prognostic marker and suggest functional consequences of LPL overexpression in patients with B-CLL are suggested and a trend for a shorter median overall survival is suggested.
LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
LPL expression is the strongest RNA-based prognostic marker in chronic lymphocytic leukemia that could potentially be applied to predict outcome in the clinical setting, particularly in the large group of patients with favorable prognosis.
Expression level of lipoprotein lipase and dystrophin genes predict survival in B-cell chronic lymphocytic leukemia
Mutational status of immunoglobulin variable region genes (VH-genes) is known as the strongest predictor of long term prognosis in B-CLL. However, applications in the routine clinical practice are
The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia.
Although the zeta-associated protein of 70 kDa (ZAP-70) is overexpressed in patients with chronic lymphocytic leukemia (CLL) displaying unmutated IGVH genes and poor prognosis, a previous microarray